ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "FDA Approval: Perioperative Pembrolizumab and KEYNOTE 671"
Episode Synopsis
Host Dr. Narjust Florez leads a discussion about the data from the KEYNOTE 671 trial, presented at ASCO 2023 and ESMO 2023, that led to the first approval of the combination of pembrolizumab plus chemotherapy in the neoadjuvant and adjuvant setting.
More episodes of the podcast Lung Cancer Considered
LCC in Greek: WCLC 2025 Highlights
10/10/2025
LCC in Arabic: WCLC 2025 Highlights
03/10/2025
Lung Cancer Considered: Targeting EGFR NSCLC
03/10/2025
LCC in Korean: WCLC 2025 Highlights
30/09/2025
In God we trust